12:20 PM EDT, 10/25/2024 (MT Newswires) -- ImmunityBio ( IBRX ) shares were rallying 40% Friday after the company said Thursday it dosed the first patients in a phase 1 trial that will assess its CAR-NK cellular therapy as a potential treatment for non-Hodgkin's lymphoma.

The Quilt 106 trial will initially use CD19-targeted high-affinity natural killer cells alone and, if proven safe, will combine them with rituximab for patients with certain CD19+ and CD20+ relapsed B-cell non-Hodgkin's lymphoma, the company said.

The phase 1 study will involve up to 10 participants and take place in three South African cities, it added.

ImmunityBio ( IBRX ) said it expects to complete patient enrollment by Q1 2025, with initial trial results anticipated in H2.

Price: 5.89, Change: +1.68, Percent Change: +39.90